Folate Supplementation In Pregnancy Research Articles

Prophylaxis With Iron and Folate Supplementation in Pregnancy; A Health Facility-Based Assessment of Its Role for Prevention of Anaemia at Delivery

Objective: Presumptive Iron and folate supplementation, (IFS), for both healthy and irondeficient pregnant women in developing countries, is aimed to ameliorate the high prevalence of maternal anaemia.1 This may be valuable only in selected women.13 Its role for averting maternal anaemia at delivery is therefore analysed.Methodology: The hospital-based cross-sectional study enrolled 413 ANC attendant parturients, exposed to IFS prior to delivery. Anaemia in pregnancy was classified by specifications of the Indian Council of Medical Research (ICMR) using maternal pre-deliveryhaemoglobin concentrations. Maternal haemoglobin concentrations and differential patterns of exposure to IFS were analysed across various maternal and environmental variables with epi info 3.5.4.Results: Parturients were mostly aged 25-34 years and largely exposed to IFS for ≥ 6 months during pregnancy. Anaemic parturients, (typically defined by lower maternal age), initiated ANC attendance later than non-anaemic parturients. Patterns of maternal anaemia varied insignificantly despite differential patterns of duration of IFS and subjectively assessed degree of compliance. Self-reported full compliance with IFS weakly correlated with higher maternal Hgb concentrations. Mean maternal Hgb concentrations remained consistent with mild anaemia irrespective of duration of IFS.Conclusion: Despite weak correlates between maternal anaemia and degree of compliance, the capacity of IFS to prevent mild, moderate or severe maternal anaemia remains unclear.Recommendation: Indiscriminate IFS for all pregnant women, regardless of their Hgb concentrations, should be reviewed while investigation of factors that may underlie maternal non-response to routine IFS should be prioritized.

Folate supplementation in pregnancy

Objectives: To determine the prevalence of low, normal and high folate levels in Omani population. Folate supplement given routinely during pregnancy. Folate added into multi-vitamins supplement as well as into food products. This leads to decrease the prevalence of low folate or increase prevalence of people with excess folate. Low and high folate level leads to adverse side effects.
 Methods: 3706 folate samples analyzed in Cobas e 601 chemical analyzer. The results separated into three main groups (low, normal and high).
 Results: Only 0.3% of the study sample shows low folate level. Five (0.2%) out of 2335 female samples show low folate level. Three (0.2%) out of 1371 male samples shows low folate level.
 Conclusion: Routine folate intake during pregnancy, supplement to the general population for wellbeing and food fortification might lead to excess folate status. Folate testing before supplementation help in avoiding high folate adverse effects.

What are the benefits of folate supplementation in pregnancy?

What are the benefits of folate supplementation in pregnancy?

Folate supplementation in pregnancy and gene specific DNA methylation

ObjectivesPericonceptual folate supplementation is recommended to reduce the risk of fetal neural tube defect and other congenital defects. Folate is a source of methyl donors, and experimental data on rodents...

O407 Folate supplementation in pregnancy can affect gene specific DNA methylation

International Journal of Gynecology & ObstetricsVolume 107, Issue S2 p. S208-S208 Free communication (oral) presentations O407 Folate supplementation in pregnancy can affect gene specific DNA methylation E. Karpova, E. KarpovaSearch for more papers by this authorR. Emes, R. EmesSearch for more papers by this authorW. Carroll, W. CarrollSearch for more papers by this authorA. Fryer, A. FryerSearch for more papers by this authorK. Ismail, K. IsmailSearch for more papers by this authorW. Farrell, W. FarrellSearch for more papers by this author E. Karpova, E. KarpovaSearch for more papers by this authorR. Emes, R. EmesSearch for more papers by this authorW. Carroll, W. CarrollSearch for more papers by this authorA. Fryer, A. FryerSearch for more papers by this authorK. Ismail, K. IsmailSearch for more papers by this authorW. Farrell, W. FarrellSearch for more papers by this author First published: 06 October 2011 https://doi.org/10.1016/S0020-7292(09)60780-3AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume107, IssueS2Abstracts of XIX FIGO World Congress of Gynecology and ObstetricsOctober 2009Pages S208-S208 RelatedInformation

5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL)

The reported correlation of defects in 5,10-methylenetetrahydrofolate reductase (MTHFR), the key enzyme of folate metabolism, with modulated risk for acute lymphoblastic leukemia (ALL) is ambiguous. We have elucidated the influence of MTHFR genotype on ALL development and relapse in 140 Slovenian pediatric ALL patients and 183 healthy controls. A decreased proportion of low activity MTHFR genotypes was found in a group of ALL patients with relapses compared to healthy controls ( p = 0.022) and ALL cases without relapse ( p = 0.027). Mutations in the MTHFR gene decrease the onset risk of ALL with relapse in the setting of no folate supplementation in pregnancy, but not of relapse-free ALL.

WITHDRAWN: Folate supplementation in pregnancy.

Folate depletion may result in anaemia during pregnancy. The objective of this review was to assess the effects of folate supplementation in pregnancy on haematological and biochemical parameters and measures of pregnancy outcome. This review did not address the role of periconceptual folate supplementation to diminish the risk of fetal malformation. A comprehensive electronic search included that of the Cochrane Pregnancy and Childbirth Group trials register. Date of last search: October 2001. Acceptably controlled trials of folate supplementation compared with placebo or no treatment to pregnant women with normal haemoglobin levels. Trial quality was assessed. Study authors were contacted for additional information when necessary. Twenty-one studies were included. The trials varied in quality. Compared to placebo or no supplementation, folate supplementation was associated with increased or maintained serum folate levels (odds ratio 0.18, 95% confidence interval 0.13 to 0.24) and red cell folate levels (odds ratio 0.18, 95% confidence interval 0.09 to 0.38). Folate supplementation was associated with a reduction in the proportion of women with low haemoglobin level in late pregnancy (odds ratio 0.61, 95% confidence interval 0.52 to 0.71) and megaloblastic erythropoiesis (odds ratio 0.65, 95% confidence interval 0.45 to 0.95). Apart from a possible reduction in the incidence of low birthweight, folate supplementation appears to have no measurable effect on any other substantive measures of pregnancy outcome. Folate supplementation during pregnancy appears to improve haemoglobin levels and folate status. There is not enough evidence to evaluate whether folate supplementation has any effect, beneficial or harmful, on clinical outcomes for mother and baby.

WITHDRAWN: Iron and folate supplementation in pregnancy.

Anaemia in pregnancy is a major health problem in many developing countries where nutritional deficiency, malaria and other parasitic infections contribute to increased maternal and perinatal mortality and morbidity. The objective of this review was to assess the effects of routine iron and folate supplementation on haematological and biochemical parameters and on pregnancy outcome. The Cochrane Pregnancy and Childbirth Group trials register was searched. Study authors were also contacted. Acceptably controlled trials of routine iron and folate supplementation for pregnant women. Eligibility and trial quality were assessed by one reviewer. Study authors were contacted for additional information. Eight trials involving 5449 women were included. Routine supplementation with iron or folate raised or maintained the serum iron and ferritin levels and serum and red cell folate levels. Supplementation resulted in a substantial reduction of women with a haemoglobin level below 10 or 10.5 grams in late pregnancy. Routine supplementation with iron and folate had no detectable effect on any substantive measures of either maternal or fetal outcome. Routine supplementation with iron and folate appears to prevent low haemoglobin at delivery. There is very little information on other outcomes for either mother or baby. There are few data derived from communities where iron and folate deficiency is common and anaemia is a serious health problem.

Taking folate in pregnancy and risk of maternal breast cancer

Taking folate before conception and then for the first three months of pregnancy reduces the risk of recurrence of neural tube defects,1 and fortification of food has been proposed. The...

Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case-control study

Acute lymphoblastic leukaemia is the most common childhood cancer in more-developed countries but it has few recognised risk factors or preventive measures. We aimed to determine and assess the risk factors associated with this disease. From 1984 to 1992, we investigated known and suspected risk factors for common acute lymphoblastic leukaemia diagnosed in a population-based case-control study of children aged 0-14 years in Western Australia. 83 children in the study group came from the sole referral centre for paediatric cancer in the state and 166 controls matched for age and sex were recruited through a postal survey of people randomly selected from the state electoral roll. We interviewed mothers of 83 study and 166 control children (82% and 74%, respectively, of those eligible). Fathers completed a self-administered questionnaire. We recorded a protective association between iron or folate supplementation in pregnancy and risk of common acute lymphoblastic leukaemia in the child (odds ratio 0.37 [95% CI 0.21-0.65]; p=0.001). For iron alone, the odds ratio was 0.75 (0.37-1.51); only one mother took folate without iron. Further analyses of folate use with or without iron (0.40; 0.21-0.73) showed that the protective effect varies little by time of first use of supplements or for how long they were taken. The association was not weakened by adjustment for potentially confounding variables. Our results, though unexpected, suggest that folate supplementation in pregnancy reduces the risk of common acute lymphoblastic leukaemia in the child.

Hypothesis: folate-responsive neural tube defects and neurocristopathies.

What accounts for the wide spectrum of folate-responsive dysmorphogeneses? Both embryonic and fetal cells are entirely dependent on maternal folate to support their requirement for precisely timed proliferative bursts during gestation. Folate receptors (FRs) mediate transport into cells and are central to transplacental maternal-to-fetal folate transport. FRs are also critical for neural tube and neural crest development because recent murine "knock-out" and "knock-down" of FRs results in a high percentage of folate-responsive neural tube defects (NTDs) and neurocristopathies. Central to our hypothesis is the fact that folate deficiency is accompanied by a reduction in the proliferative capacity of highly mitotic neural tube or neural crest cells. Therefore, depending on when in pregnancy various cohorts of highly proliferative cells are deprived of folate, and the origin of the affected cells will determine the type of developmental dysmorphogenesis. Thus, selective folate deficiency in early pregnancy of only highly proliferative neural tube or neural crest cells predisposes to NTDs or gross dysmorphogenesis, respectively. Folate deficiency that compromises placental development will predispose to small-for-date babies due to an overall nutrient deficiency, and the development of folate insufficiency later in pregnancy could predispose to more subtle midline birth defects involving atresia of neural crest cell-derived structures. Finally, a congenital folate transport defect would only be corrected by suprapharmacological doses of folate, which ensures passive diffusion. This hypothesis can explain the results of several earlier and more recent clinical trials on folate supplementation in pregnancy, but it also raises the possibility that there may be several as yet undiscovered neurocristopathies that are folate responsive. Teratology 62:42-50, 2000. Published 2000 Wiley-Liss, Inc.

Iron and folate supplementation in pregnancy.

Anaemia in pregnancy is a major health problem in many developing countries where nutritional deficiency, malaria and other parasitic infections contribute to increased maternal and perinatal mortality and morbidity. The objective of this review was to assess the effects of routine iron and folate supplementation on haematological and biochemical parameters and on pregnancy outcome. The Cochrane Pregnancy and Childbirth Group trials register was searched. Study authors were also contacted. Acceptably controlled trials of routine iron and folate supplementation for pregnant women. Eligibility and trial quality were assessed by one reviewer. Study authors were contacted for additional information. Eight trials involving 5449 women were included. Routine supplementation with iron or folate raised or maintained the serum iron and ferritin levels and serum and red cell folate levels. Supplementation resulted in a substantial reduction of women with a haemoglobin level below 10 or 10.5 grams in late pregnancy. Routine supplementation with iron and folate had no detectable effect on any substantive measures of either maternal or fetal outcome. Routine supplementation with iron and folate appears to prevent low haemoglobin at delivery. There is very little information on other outcomes for either mother or baby. There are few data derived from communities where iron and folate deficiency is common and anaemia is a serious health problem.

Folate supplementation in pregnancy.

Folate depletion may result in anaemia during pregnancy. The objective of this review was to assess the effects of folate supplementation in pregnancy on haematological and biochemical parameters and measures of pregnancy outcome. This review did not address the role of periconceptual folate supplementation to diminish the risk of fetal malformation. A comprehensive electronic search included that of the Cochrane Pregnancy and Childbirth Group trials register. Acceptably controlled trials of folate supplementation compared with placebo or no treatment to pregnant women with normal haemoglobin levels. Trial quality was assessed. Study authors were contacted for additional information when necessary. Twenty-one studies were included. The trials varied in quality. Compared to placebo or no supplementation, folate supplementation was associated with increased or maintained serum folate levels (odds ratio 0.18, 95% confidence interval 0.13 to 0.24) and red cell folate levels (odds ratio 0.18, 95% confidence interval 0.09 to 0.38). Folate supplementation was associated with a reduction in the proportion of women with low haemoglobin level in late pregnancy (odds ratio 0.61, 95% confidence interval 0.52 to 0.71) and megaloblastic erythropoiesis (odds ratio 0.65, 95% confidence interval 0.45 to 0.95). Apart from a possible reduction in the incidence of low birthweight, folate supplementation appears to have no measurable effect on any other substantive measures of pregnancy outcome. Folate supplementation during pregnancy appears to improve haemoglobin levels and folate status. There is not enough evidence to evaluate whether folate supplementation has any effect, beneficial or harmful, on clinical outcomes for mother and baby.